Introduction {#sec1}
============

Metabolomics is a growing field that has yielded numerous metabolites with abundant changes correlating to a variety of diseases and phenotypes.^[@ref1],[@ref2]^ However, a major challenge in mass spectrometry (MS)-based metabolomics research has been the structural confirmation of individual metabolites, including differentiation of targeted metabolites from those compounds that share an identical monoisotopic mass and are of the same chemical class, as well as identification of metabolites that are not currently listed in available metabolite databases.^[@ref1],[@ref3],[@ref4]^ The structural elucidation of a small-molecule metabolite can be a complex and time-consuming process.^[@ref3],[@ref5]^ This is particularly true when de novo characterization is required ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and even automated methods used to search tandem-MS (MS/MS) data against established metabolite databases only predict the metabolite's structure.^[@ref6]^ A putative chemical identification can be achieved by interrogating available metabolite databases with an experimentally derived accurate mass, *m*/*z*, or a molecular formula.^[@ref3],[@ref7],[@ref8]^ Further confidence in the putative identification can be obtained by in silico database analyses using the targeted analyte's experimental fragmentation pattern (MS/MS or MS*^n^* spectra).^[@ref3],[@ref7],[@ref8]^ However, a confirmed structural identification is only achieved by demonstrating that the targeted metabolite has the same properties (accurate mass, MS/MS spectra, and retention time (RT)) as an authentic chemical standard under identical analytical conditions.^[@ref3],[@ref7],[@ref8]^ Owing to the complexity of metabolic processes, a large number of small molecules observed in biological samples are not annotated in the available metabolite databases, nor do they have authentic chemical standards. In fact, more than 50% of the small molecules observed in four recent metabolomics studies were labeled as unidentified.^[@ref9]−[@ref12]^ This limitation in untargeted metabolomics studies results in an underestimation of the chemical diversity and biological importance of small molecules present in biological samples and underscores the need for continued elucidation of novel metabolite structures.

![Processes required for structural identification of molecular features (MFs) detected via untargeted LC--MS-based metabolomics and the different levels of identification based on guidelines provided by the Metabolomics Standards Initiatives.^[@ref3],[@ref8]^ The accurate mass of an MF of interest is interrogated against existing databases, a match to one or more annotated metabolites provides a putative identification, level 3. MS/MS spectrum of a level 3 metabolite or MF with no matches to annotated metabolites still provides increased structural information. A direct match of the experimental MS/MS spectrum to that of an annotated metabolite provides a level 2 putative structural identification. A partial match of the experimental MS/MS spectrum to that associated with one or more annotated metabolites can be used to derive a hypothesis for the metabolite structure, and experimental approaches can be undertaken to further elucidate or confirm the structure. This can be an iterative approach. A direct match of the metabolite's mass, MS/MS spectra, and RT to that of an authentic standard under identical analytical conditions provides for full confirmation of structural identification, level 1 identity. The inability to use experimental mass or MS/MS data to identify or elucidate a structure results in the MF being designated as an unknown compound, level 4.](ao-2017-00872k_0001){#fig1}

Previously, application of untargeted liquid chromatography (LC)--MS-based metabolomics to select small-molecule biomarkers of treatment response in tuberculosis (TB) patients identified 12 candidate biomarkers.^[@ref10]^ Seven of these small molecules, also referred to as MFs, were matched via their accurate masses to compounds in the METLIN metabolite database or Human Metabolome Database (HMDB), giving them putative identifications; however, none of the identifications was confirmed. One of these MFs (MF 202.1326), defined by an accurate mass of 202.1326 Da and an RT of 3.89 min, was given a putative identification of a dipeptide containing isoleucine/leucine and alanine.^[@ref10]^ In this current study, efforts to fully elucidate the structure of this MF revealed that it was not a dipeptide, but a product with a previously unrecognized structure. MS/MS along with chemical and enzymatic synthesis provided a confirmed identity for the MF as *N*^1^-acetylisoputreanine, a catabolite of polyamine metabolism that had been predicted^[@ref13],[@ref14]^ but had not been detected in human biological fluids before this study.

Results and Discussion {#sec2}
======================

LC--MS/MS Investigation of a Structurally Undefined MF {#sec2.1}
------------------------------------------------------

MF 202.1326, a putative metabolite of urine with an experimentally determined accurate mass of 202.1326 Da and a predicted formula of C~9~H~18~N~2~O~3~, displayed relative shifts in abundance correlating with anti-TB therapy and was given a putative structural identification of a dipeptide containing isoleucine/leucine and alanine.^[@ref10]^ An evaluation of a leucyl-alanine standard revealed an 11.097 min RT using reverse-phase chromatography, and this was significantly different from the 3.707 min RT of endogenous MF 202.1326 ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). This not only established that MF 202.1326 was not leucyl-alanine, but that MF 202.1326 was unlikely to contain a nonpolar side chain like that of leucine and isoleucine.

![LC--MS and LC--MS/MS of MF 202.1326 to provide structural information. (A) Extracted ion chromatogram (EIC) of *m*/*z* 203.1390 from LC--MS data of human urine spiked with leucyl-alanine standard. The peak at 3.7 min is MF 202.1326. The peak at 11.1 min is leucyl--alanine. (B) LC--MS/MS spectra of MF 202.1326 at three collision energies; 10 V (top), 20 V (middle), and 40 V (bottom). (C) LC--MS/MS spectrum of MF 202.1326 (top) compared to that of *N*^1^-acetylspermine (middle) and *N*^1^,*N*^12^-diacetylspermine (bottom). All spectra were obtained with a collision energy of 20 V. The fragment ions *m*/*z* 100.076, 72.045, and 58.066 are present in the spectra of all three compounds.](ao-2017-00872k_0002){#fig2}

To gain insight into the structure of MF 202.1326, we applied LC--MS/MS ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). The fragment ions *m*/*z* 185.128, 126.091, 100.076, 72.045, and 58.066 were recurrent regardless of the collision energy applied, indicating that they were specific fragments originating from the intact molecule. The fragment ion *m*/*z* 100.076 was highly abundant even at lower collision energies. This was representative of fragmentation occurring at a highly labile bond such as a C--N bond.

Molecules with similar structures or of the same class can share identical fragment ions.^[@ref15],[@ref16]^ To assess this possibility for MF 202.1326, we queried the National Institute of Standards and Technology (NIST) MS/MS spectral database to determine whether partial matches occurred between the MS/MS spectrum of MF 202.1326 and the annotated spectra of known compounds. A partial match to the MS/MS spectrum of *N*^1^-acetylspermine with fragment ions *m*/*z* 100.076, 72.045, and 58.066 was obtained. These common fragment ions are also present in the available METLIN and HMDB MS/MS spectra for two other acetylated polyamines, *N*^1^-acetylspermidine and *N*^1^,*N*^12^-diacetylspermine. Using authentic standards for *N*^1^-acetylspermine and *N*^1^,*N*^12^-diacetylspermine, we confirmed that these annotated fragment ions were replicated in MS/MS experiments with our instrument ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C). Interestingly, all three compounds shared the dominant *m*/*z* 100.076 fragment ion.

Establishing the Hypothesis for *N*^1^-Acetylisoputreanine as the Structure of MF 202.1326 {#sec2.2}
------------------------------------------------------------------------------------------

Theoretical fragmentation of *N*^1^-acetylspermine indicated that the *m*/*z* 100.076 fragment ion originated from fragmentation of the C--N bond that separates the acetamidopropyl group and spermidine ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). To demonstrate that the *m*/*z* 100.076 fragment ion of MF 202.1326 also represents an acetamidopropyl group, we targeted this product ion for further fragmentation using an improvised MS^3^ approach. Specifically, increased fragmentor voltage was applied to induce in-source fragmentation and generate the *m*/*z* 100.076 fragment ion for subsequent MS^3^ fragmentation in the collision cell.^[@ref17],[@ref18]^ Throughout this article, MS^3^ refers to results obtained using this improvised MS^3^ approach. The MS^3^ fragmentation spectra of *m*/*z* 100.076 derived from MF 202.1326 and *N*^1^-acetylspermine were nearly identical ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). This signified that both molecules possessed an acetamidopropyl group. Theoretical fragmentation of the acetamidopropyl group provided additional support for the structural identity of the *m*/*z* 100.076 fragment ion ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). Specifically, the MS^3^ fragments *m*/*z* 58.066 and 43.018 would have resulted from fragmentation of the labile C--N separating the acetyl group and propylamine ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B,C). *N*^1^-Acetylspermine is a monoacetyl conjugate produced during polyamine metabolism. Acetylation of polyamines reduces the charge of these molecules and facilitates their export from the cell, as well as increases metabolic flux through the polyamine pathway.^[@ref19],[@ref20]^ The presence of an acetamidopropyl group in MF 202.1326 led us to infer that it might also be involved in polyamine metabolism.

![MS^3^ analysis of the *m*/*z* 100.076 fragment ion of MF 202.1326 and *N*^1^-acetylspermine. (A) Structure of *N*^1^-acetylspermine and the predicted origin of the *m*/*z* 100.076 fragment ion based on theoretical fragmentation. (B) MS^3^ fragmentation of *m*/*z* 100.076 from MF 202.1326 (top) and *N*^1^-acetylspermine (bottom). (C) Theoretical fragmentation tree used to derive the structure of the *m*/*z* 100.076 fragment ion.](ao-2017-00872k_0003){#fig3}

Typical fragmentation of a parent ion can generate a charged fragment and a corresponding neutral fragment, the latter of which is not detected in the MS/MS spectra. Thus, having determined that one portion of MF 202.1326 contained an acetamidopropyl group, a neutral loss fragment of 103.063 Da was hypothesized ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The 103.063 Da neutral loss fragment was interrogated against the ChemSpider database, and 150 potential structures were matched to this mass, with γ-aminobutyric acid (GABA) being the highest ranked. GABA is also produced during polyamine metabolism^[@ref13]^ leading us to hypothesize that C-3 of the acetamidopropyl group was linked to the sole nitrogen of GABA, creating a C--N bond in MF 202.1326 similar to that of *N*^1^-acetylspermine (compare [Figures [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A and [4](#fig4){ref-type="fig"}). Additional support for the predicted structure of MF 202.1326 was the *m*/*z* 185.128 fragment ion ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B) that was indicative of a neutral loss of water via fragmentation of the −OH group in GABA. This structure matched with a predicted, but never detected, catabolite of polyamine metabolism, *N*^1^-acetylisoputreanine^[@ref13]^ ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![Hypothesized structure of MF 202.1326, *N*^1^-acetylisoputreanine. Fragmentation at the proximal C--N bond would yield an *m*/*z* 100.076 fragment ion \[M + H\]^+^ attributed to an acetamidopropyl group, and a neutral loss of 103.0633 Da \[M\] can be attributed to a hypothesized GABA constituent.](ao-2017-00872k_0004){#fig4}

Confirmation of MF 202.1326 as *N*^1^-Acetylisoputreanine {#sec2.3}
---------------------------------------------------------

Confirmation of the structural identity of MF 202.1326 as *N*^1^-acetylisoputreanine required an authentic chemical standard, but one was not commercially available. Thus, a combined enzymatic and chemical synthesis approach was employed to generate a standard compound ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). This approach exploited a previously purified and enzymatically characterized amine oxidase, *N*^1^-acetylpolyamine oxidase (PAOX), which produces the reactive aldehyde, 3-acetamidopropanol, upon catabolism of *N*^1^-acetylspermine and *N*^1^-acetylspermidine.^[@ref13],[@ref21]^ The addition of PAOX to *N*^1^-acetylspermine ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B) resulted in the formation of 3-acetamidopropanol and spermidine ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C), and the addition of excess GABA in the presence of the reducing agent allowed the formation of *N*^1^-acetylisoputreanine ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D). In the absence of PAOX, GABA, or a reducing agent, there was no formation of *N*^1^-acetylisoputreanine in the positive mode (data not shown). The MS/MS spectra for the synthetic compound and the endogenous MF 202.1326 were identical, confirming that the unknown metabolite is *N*^1^-acetylisoputreanine ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B). Further confirmation was achieved by spiking the synthetic compound into urine, which yielded an increase in the endogenous MF 202.1326 peak ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A).

![Enzymatic and chemical synthesis of *N*^1^-acetylisoputreanine. (A) Diagram of the method used for enzymatic formation of 3-acetamidopropanol (box, solid line) and the subsequent generation of *N*^1^-acetylisoputreanine by the addition of GABA (box, dotted line). Reactions were performed in a single tube with sequential addition of reagents. (B--D) EICs from LC--MS analyses at different stages of the reaction. The *m*/*z* values of 245.234, 146.166, 116.071, and 203.139 were used in the EIC to monitor for *N*^1^-acetylspermine, spermidine, 3-acetamidopropanol, and *N*^1^-acetylisoputreanine, respectively. (B) *N*^1^-acetylspermine before the addition of PAOX. (C) Analysis of products after incubation with PAOX. (D) Analysis of products after reaction with GABA.](ao-2017-00872k_0005){#fig5}

![LC--MS and MS/MS confirmation of MF 202.1326 as *N*^1^-acetylisoputreanine. (A) EIC for *m*/*z* 203.1390 from patient urine, synthetic standard reaction mixture, and patient urine spiked with synthetic standard reaction mixture. (B) MS/MS spectra for MF 202.1326 and synthetic standard at collision energies of 10 V (top two panels) and 20 V (bottom two panels).](ao-2017-00872k_0006){#fig6}

Both *N*^1^-Acetylisoputreanine and *N*^1^-Acetylisoputreanine-γ-lactam Are Endogenous Components of Human Urine {#sec2.4}
----------------------------------------------------------------------------------------------------------------

There has been no previous report of *N*^1^-acetylisoputreanine in biological samples; however, the γ-lactam form of *N*^1^-acetylisoputreanine, *N*-(3-acetamidopropyl)pyrrolidin-2-one, was previously described and quantified in urine.^[@ref22],[@ref23]^ One possibility for *N*^1^-acetylisoputreanine not being detected in the previous studies was the use of gas chromatography (GC)--MS to detect metabolites extracted from urine without prior derivatization. Owing to the polarity of the carboxylic acid, *N*^1^-acetylisoputreanine would have lacked the proper volatility for GC--MS or failed to be extracted with dichloromethane. It is also noted that other studies describe the detection of nonconjugated isoputreanine in the urine of animals following their exposure to spermidine.^[@ref24]−[@ref26]^ However, the urine was subjected to acid hydrolysis before detection, and this would have hydrolyzed the γ-lactam ring and removed acetyl groups; thus, it was concluded that isoputreanine-γ-lactam and *N*^1^-acetylisoputreanine-γ-lactam were the natural excretory products following oxidative deamination of spermidine and *N*^1^-acetylspermidine, respectively.^[@ref14]^

We wanted to confirm the presence of *N*^1^-acetylisoputreanine-γ-lactam in human urine using our analytical methods. A peak with the *m*/*z* value of 185.129 corresponding to *N*^1^-acetylisoputreanine-γ-lactam was present in the urine ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A). This *m*/*z* 185.129 peak had the same RT and MS/MS fragmentation as those of a synthetic standard and addition of the standard compound to the urine resulted in an increase in the endogenous peak ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A,B). Because *N*^1^-acetylisoputreanine-γ-lactam is presumed to be the natural excretory product, we assessed whether *N*^1^-acetylisoputreanine was a potential artifact of the analytical method we applied. Analysis of synthetic *N*^1^-acetylisoputreanine-γ-lactam on its own using our analytical method did not result in an additional peak for *N*^1^-acetylisoputreanine ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A). This provided evidence that hydrolysis of the γ-lactam ring was not occurring during the assay. There are also enzymes present in the urine that could lead to enzymatic interconversion between *N*^1^-acetylisoputreanine and *N*^1^-acetylisoputreanine-γ-lactam.^[@ref27]^ Thus, fresh human urine was evaluated for enzymatic interconversion. The addition of *N*^1^-acetylisoputreanine-γ-lactam to fresh urine followed by incubation at room temperature for 24 h did not alter the abundance of *N*^1^-acetylisoputreanine ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A), and the levels of endogenous *N*^1^-acetylisoputreanine and *N*^1^-acetylisoputreanine-γ-lactam did not noticeably change over 24 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). If enzymatic interconversion between the two compounds had occurred, a decrease in the peak area of one compound and a corresponding increase in the peak area of the other would have been observed. This did not occur ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). These evaluations provide strong evidence that *N*^1^-acetylisoputreanine and *N*^1^-acetylisoputreanine-γ-lactam are endogenous components of human urine; there is no enzymatic interconversion; and *N*^1^-acetylisoputreanine does not result from spontaneous hydrolysis of the ring structure of *N*^1^-acetylisoputreanine-γ-lactam.

![LC--MS and MS/MS analysis of *N*^1^-acetylisoputreanine-γ-lactam in patient urine. (A) EIC for *m*/*z* 185.1285 and *m*/*z* 203.1390 (inset) from *N*^1^-acetylisoputreanine-γ-lactam synthetic standard, patient urine spiked with *N*^1^-acetylisoputreanine-γ-lactam synthetic standard, and patient urine. (B) MS/MS spectrum comparison for *N*^1^-acetylisoputreanine-γ-lactam from urine and synthetic standard.](ao-2017-00872k_0007){#fig7}

###### Stability (24 h) of Endogenous *N*^1^-Acetylisoputreanine and *N*^1^-Acetylisoputreanine-γ-lactam in Fresh Urine at Room Temperature

             *N*^1^-acetylisoputreanine   *N*^1^-acetylisoputreanine-γ-lactam                                    
  ---------- ---------------------------- ------------------------------------- ------ ------------ ------------ --------
  sample 1   8 502 132                    7 852 119                             7.95   17 655 963   17 096 067   3.22
  sample 2   6 413 762                    6 056 531                             5.73   13 723 175   13 838 616   --0.84
  sample 3   10 029 551                   9 573 870                             4.65   17 114 405   16 497 977   3.67
  sample 4   2 053 592                    1 954 062                             4.97   4 566 251    4 488 474    1.72

Relative percent difference.

Origin of *N*^1^-Acetylisoputreanine {#sec2.5}
------------------------------------

The origin of *N*^1^-acetylisoputreanine has not been determined due to its unconfirmed existence before this study. However, the origin of *N*^1^-acetylisoputreanine-γ-lactam has been investigated. Aminoguanidine treatment of rats greatly diminished the urinary levels of *N*^1^-acetylisoputreanine-γ-lactam.^[@ref22],[@ref28]^ Because aminoguanidine is an inhibitor of copper-dependent amino oxidases (CuAO), it was concluded that *N*^1^-acetylisoputreanine-γ-lactam is formed due to amine oxidation of *N*^1^-acetylspermidine by CuAO, followed by aldehyde dehydrogenase (ALDH) activity ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}).^[@ref13],[@ref22],[@ref28]^ On the basis of this, we hypothesize that *N*^1^-acetylisoputreanine is also formed due to the action of CuAO and that a separate ALDH enzyme results in *N*^1^-acetylisoputreanine rather than the γ-lactam form ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}).^[@ref29]^ Further studies are required to confirm the enzymes involved in the formation of *N*^1^-acetylisoputreanine and to determine the mechanisms underlying its association with TB treatment.

![Polyamine interconversion cycle including proposed pathways for the formation of *N*^1^-acetylisoputreanine and *N*^1^-acetylisoputreanine-γ-lactam. Adapted from ref ([@ref13]).](ao-2017-00872k_0008){#fig8}

Polyamine metabolism, a metabolic pathway with increasing interest, has been examined in relation to cancer and other diseases using metabolomics-based techniques.^[@ref30]−[@ref35]^ The polycationic property of polyamines enables these metabolites to regulate biological processes through reversible ionic interactions with negatively charged molecules such as nucleic acids, proteins, and phospholipids.^[@ref36]−[@ref41]^ Thus, polyamines act as important factors in cell growth and differentiation, requiring their levels to be tightly regulated via the polyamine interconversion cycle and cellular transport ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}).^[@ref13],[@ref42]^ Therefore, a flux in polyamine levels during a disease state likely reflects a perturbation of these homeostasis mechanisms. Elucidation of all products of polyamine metabolism will allow for a better understanding of their biological roles and how they are regulated during disease.

Conclusions {#sec3}
===========

A combination of LC--MS fragmentation along with enzymatic and chemical approaches was utilized to confirm the structure of a significant but previously unidentified metabolite, *N*^1^-acetylisoputreanine. The presented data established that both *N*^1^-acetylisoputreanine and the previously described *N*^1^-acetylisoputreanine-γ-lactam are endogenous products detectable in human urine. In addition, the results from this study demonstrated that metabolite identification based on database interrogation of MS data alone has significant limitations and that novel metabolites belonging to established pathways are present in biological fluid and should not be presumed as an artifact of sample analyses. Furthermore, this work underscores the importance of confirming metabolite structural identities.

Experimental Section {#sec4}
====================

Materials {#sec4.1}
---------

Glycine, *N*^1^-acetylspermine, GABA, *N*-(3-aminopropyl)pyrrolidin-2-one, acetyl chloride, and sodium triacetoxyborohydride were obtained from Sigma Aldrich (St. Louis, MO). LC--MS grade water, methanol, and acetonitrile were from Honeywell Burdick & Jackson (Muskegon, MI). Formic acid was obtained from Fischer Scientific (Pittsburgh, PA). Bulk human urine was obtained from Gemini Bio-Products (West Sacramento, CA). Fresh human urine was obtained from healthy donors at Colorado State University. Patient urine for metabolite identification was from a subset of the samples used for metabolite discovery in the previously published study.^[@ref10]^

LC and MS Analysis {#sec4.2}
------------------

Chromatography was based on the previously described method using an Agilent 1200 series high-performance LC system (Agilent Technologies; Palo Alto, CA) coupled with an Atlantis T3 reverse-phase C18 3.5 μm column (2.1 mm × 150 mm; Waters Corp., Milford, MA).^[@ref10]^ MS was performed using an Agilent 6520 quadrupole time of flight LC--MS instrument equipped with an Agilent electrospray ionization source that was operated in the positive ionization mode. The operating conditions for the mass spectrometer were: gas temperature, 300 °C; drying gas, 8 L/min; nebulizer, 45 lb/in.^2^; capillary voltage, 2000 V; fragmentation energy for MS and MS/MS, 120 V; fragmentation energy to generate the *m*/*z* 100.0757 product ion, 200 V; skimmer voltage, 60 V; and octapole RF setting, 750 V. Specified ions were subjected to MS/MS fragmentation (isolation width of 1.3 Da) by collision-induced dissociation at set collision energies (5--40 V). Data were collected in the profile and centroid modes at a scan rate of 2.0 spectra/s and a scan range of *m*/*z* 50--1700 using the Agilent MassHunter Data Acquisition software.

Purification of PAOX {#sec4.3}
--------------------

A plasmid construct (pET15b/hPAO-1) was transformed into *Escherichia coli* BL21(DE3) STAR. The expression of hPAO-1 and purification of recombinant PAOX was performed as previously described.^[@ref21]^ Nickel-nitrilotriacetic acid (Ni-NTA) resin (Qiagen; Valencia, CA) was used for immobilized metal ion affinity chromatography. Purified protein was dialyzed in 50 mM Tris--HCl (pH 8.0), 250 mM NaCl, 0.1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, and 0.2 μM flavin adenine dinucleotide, and stored at 4 °C.

Synthesis of *N*^1^-Acetylisoputreanine and *N*^1^-Acetylisoputreanine-γ-lactam {#sec4.4}
-------------------------------------------------------------------------------

A modification of the previously described enzyme assay was applied in the synthesis of *N*^1^-acetylisoputreanine.^[@ref21]^*N*^1^-acetylspermine at 0.25 mM was combined with purified recombinant PAOX (0.6 mg/mL) in 88 mM glycine buffer (pH 8.0) for 30 min at room temperature. GABA (final concentration of 10 mM) was subsequently added. An aliquot (500 μL) of this mixture was added to 4.5 mL of 90% ethanol containing 1% (w/v) sodium triacetoxyborohydride and incubated at RT for 4 h. The reaction was dried in a Savant SpeedVac and resuspended in 500 μL of water and stored at 4 °C until LC--MS analysis. Before LC--MS analysis, the synthetic compound was diluted 1:10 in water or human urine.

*N*^1^-Acetylisoputreanine-γ-lactam was synthesized as previously described.^[@ref23]^ Acetylation was performed with *N*-(3-aminopropyl)pyrrolidin-2-one (0.75 M) and acetyl chloride (0.75 M) in methanol and 0.5 M PBS (1:1) adjusted to pH 7.0 with sodium hydroxide. The reaction products were extracted with dichloromethane, dried, suspended in 2 mL of LC--MS grade water and stored at 4 °C before LC--MS analyses, the synthetic compound was diluted 1:100 in water or human urine.

Evaluation of *N*^1^-Acetylisoputreanine and *N*^1^-Acetylisoputreanine-γ-lactam in Fresh Urine {#sec4.5}
-----------------------------------------------------------------------------------------------

Fresh urine obtained from healthy donors was stored at 4 °C and processed within 4 h of collection. An initial aliquot of fresh urine was stored at −20 °C as the 0 h time point sample. To a 90 μL aliquot of urine, either 10 μL of water or *N*^1^-acetylisoputreanine-γ-lactam was added, and the sample was kept at room temperature for 24 h. The 0 and 24 h time point samples were analyzed by LC--MS. The relative abundance for *N*^1^-acetylisoputreanine and *N*^1^-acetylisoputreanine-γ-lactam was determined as the peak area on the basis of an EIC of their respective \[M + H\]^+^*m*/*z* values. The peak areas for the 24 h time point sample were corrected by dividing the peak area by 0.9. The relative percent difference between the 0 (*x*~1~) and the 24 h (*x*~2~) time points was calculated for each molecule using the following equation

Data Analyses {#sec4.6}
-------------

The LC--MS/MS spectra were manually interrogated against available MS/MS spectra in the METLIN metabolite database, HMDB, and NIST.^[@ref43]−[@ref45]^ Theoretical fragment ions for individual structures were obtained using ACD/MS Fragmenter (Advanced Chemistry Development, Inc.; Toronto, ON, Canada).

The MS/MS spectra for *N*^1^-acetylisoputreanine and *N*^1^-acetylisoputreanine-γ-lactam have been submitted to Metabolomics Workbench and will be submitted to METLIN and HMDB.
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